Urologix, Inc.
ULGXOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$2182
P/E Ratio—
52W High$0.0126
52W Low$0.0001
Urologix, Inc. (ULGX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ULGX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2014-06 | 2013-06 | 2012-06 | 2011-06 | 2010-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $14.23M | $16.59M | $17.03M | $12.57M | $14.77M |
| Cost of Revenue | $8.14M | $8.41M | $8.64M | $6.03M | $6.57M |
| Gross Profit | $6.09M | $8.18M | $8.38M | $6.54M | $8.20M |
| Gross Margin %(computed) | 42.80% | 49.32% | 49.23% | 52.03% | 55.53% |
| Operating Expenses | |||||
| R&D Expenses | $1.63M | $2.27M | $2.19M | $2.24M | $1.83M |
| G&A Expenses | $2.30M | $2.52M | $3.39M | $0.00M | $0.00M |
| Total Operating Expenses | $10.09M | $11.95M | $12.53M | $10.27M | $10.46M |
| Operating Income | ($6.93M) | ($3.92M) | ($4.14M) | ($3.73M) | ($2.26M) |
| Operating Margin %(computed) | -48.68% | -23.64% | -24.34% | -29.64% | -15.28% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.69M | $0.56M | $0.48M | $0.00M | $0.00M |
| Income Before Tax | ($7.62M) | ($4.28M) | ($4.64M) | ($3.73M) | ($2.26M) |
| Income Tax Expense | ($0.02M) | $0.01M | $0.06M | $0.01M | ($0.09M) |
| Net Income | ($7.61M) | ($4.29M) | ($4.70M) | ($3.73M) | ($2.17M) |
| Net Margin %(computed) | -53.45% | -25.87% | -27.57% | -29.70% | -14.68% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.36 | $-0.21 | $-0.32 | $-0.26 | $-0.15 |
| Wtd Avg Shares | 21.22M | 20.70M | 14.74M | 14.56M | 14.51M |
| EBITDA | ($6.34M) | ($3.05M) | ($3.46M) | ($3.16M) | ($1.46M) |
| EBITDA Margin %(computed) | -44.57% | -18.37% | -20.34% | -25.14% | -9.91% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Urologix, Inc. data
About Urologix, Inc. (ULGX) Income Statement
Urologix, Inc. (ULGX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2014, ULGX reported revenue of $0.01B, gross profit of $0.01B (gross margin 42.80%), and net income of ($0.01B) — a net profit margin of -53.45%.
Frequently asked questions
ULGX · 4 questionsUrologix, Inc. (ULGX) reported revenue of $0.01B for 2014, down 14.2% year-over-year.
ULGX revenueULGX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08